These data suggest that the potential TRPA1 inhibitory activity of desvenlafaxine, paliperidone, and febuxostat should be further explored as possible synergistic mechanisms targeting pathology progression in animal models of multiple sclerosis. This evidence concerns the gene TRPA1 and multiple sclerosis.